PMH42 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED NORDIC COUNTRIES

Currently, negative symptoms are regarded as a core aspect of schizophrenia and considered the major contributor to low function levels and deterioration in most patients with schizophrenia. Cariprazine is the first drug enabling psychiatrists to optimally treat schizophrenia patients with negative symptoms. The main objective of this research was to assess the cost-effectiveness of cariprazine compared to risperidone, in the treatment of...